June 19th 2024
A survey of health system specialty pharmacy employees found that hybrid work significantly improved quality of life and workplace productivity.
Corticosteroids' safety affirmed in treatment of childhood asthma
March 8th 2011Children being treated with a short course of oral corticosteroids for an acute asthma attack may experience a brief and transient depression of their immune response, according to a recent study conducted by Université de Montréal.
Black box warnings accelerate reduced antipsychotic use in dementia
March 3rd 2011The rate of decline in the use of atypical antipsychotics in outpatients with dementia accelerated following a black box warning issued by FDA, according to "Trends in Antipsychotic Use in Dementia 1999-2007," a multicenter study of national Veterans Affairs data that appeared in the Archives of General Psychiatry.
TXA reduces death from bleeding in trauma patients
March 3rd 2011Tranexamic acid reduces the risk of death from bleeding without increasing the risk of vascular occlusive events or the need for surgical intervention, according to a review published in the 2011 Cochrane Database of Systematic Reviews.
Labeling change for antipsychotic drugs highlights risk to newborns
March 3rd 2011FDA has updated the pregnancy section of drug labels for the entire class of antipsychotic medications to provide more information about the potential risk of extrapyramidal signs and withdrawal symptoms in newborns whose mothers take antipsychotics during the third trimester of pregnancy.
FDA approves roflumilast for severe COPD
March 2nd 2011FDA approved the first-and-only selective phosphodiesterase type 4 inhibitor roflumilast (Daliresp, Forest Pharmaceuticals), once-daily oral tablet to decrease the frequency of exacerbations or worsening of symptoms from severe chronic obstructive pulmonary disease.
FDA approves guanfacine ER tablets to treat ADHD in children, teens
March 2nd 2011FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.
NACDS and NCPA defend TRICARE beneficiaries' right to choose community pharmacy
February 28th 2011NACDS and NCPA authored a joint letter to Senate Armed Services Committee Chairman Carl Levin (D-Mich.), emphasizing the ability of community pharmacies to help lower prescription drug costs, and the importance of maintaining the right of military families and veterans to choose where they fill their prescriptions through the TRICARE program.
Forest to acquire Clinical Data
February 23rd 2011Forest Laboratories $1.2 billion acquisition of Clinical Data, the developer of Viibryd (vilazodone HCl) for the treatment of adults with major depressive disorder, is expected to allow Forest to leverage its existing presence in the antidepressant category.
Independent pharmacies must unify to fight PBM industry
February 22nd 2011The independent pharmacy industry needs to unite and develop an internal public relations campaign to mobilize pharmacy store owners and patients to fight for their prescription rights. This was one of the suggestions made during a PBM Discussion Panel for Independent Pharmacy.